

<b>Examiner-Initiated Interview Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	09/937,754	HAMPP ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
	Susan Hanley	1651	

**All Participants:**

**Status of Application:** rejected

(1) Susan Hanley.

(3) \_\_\_\_\_.

(2) William Warren.

(4) \_\_\_\_\_.

**Date of Interview:** 3 February 2005

**Time:** 3:00

**Type of Interview:**

- ☒ Telephonic  
☐ Video Conference  
☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☒ No

If Yes, provide a brief description:

**Part I.**

Rejection(s) discussed:

*103 with regard to modification of the purple membrane form of bacteriorhodopsin by transglutaminase*

Claims discussed:

*1-17*

Prior art documents discussed:

*Gaffney*

**Part II.**

SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

*See Continuation Sheet*

**Part III.**

- ☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.  
☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: It was agreed tha the prior art does not disclose nor suggest cross-linking of bacteriorhodopsin in the purple membrane from by transglutaminase. The claims will be modified by examiner's amendment such that the limitations of claim 2 will be imported into claim 1..